Microfluidization Nanosuspensions Without Surfactants
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for formulating poorly water-soluble drugs face challenges in achieving improved bioavailability, particularly for oral administration, due to limitations in particle size reduction and stability, which affects their efficacy and convenience in dosage forms.
Innovation Solution
A microfluidization process is used to create oral nanosuspensions of poorly soluble drugs without surfactants, involving the steps of stirring micronized drugs in an aqueous polymeric excipient solution followed by high-shear microfluidization, enabling stable and long-term storage and administration with enhanced bioavailability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If high-pressure homogenization or high-energy wet milling is used to reduce particle size, then dissolution rate and bioavailability are improved, but production time increases significantly
Solution Approach 1:
The patent replaces traditional mechanical size reduction methods (high-pressure homogenization, high-energy wet milling) with a microfluidization process that uses controlled shear forces and turbulence in a microchannel geometry to achieve particle size reduction more efficiently
Solution Approach 2:
The invention optimizes process parameters including microfluidizer pressure (typically 15,000-30,000 psi), number of passes (typically 10-50 passes), and formulation composition to achieve rapid particle size reduction without requiring the extensive processing time of traditional methods
2Manufacturing precision
If multiple passes through microfluidizer are used to achieve sufficient particle size reduction, then nanometer-scale particles are produced, but the process becomes time-consuming
Solution Approach 1:
The patent performs preliminary micronization of the drug substance before microfluidization, creating a head start that reduces the number of microfluidization passes needed to achieve final nanometer-scale particle size
Solution Approach 2:
The microfluidization process operates continuously with optimized flow rates and pressure settings, maintaining efficient particle size reduction throughout the process without interruption or repeated batch processing
3Manufacturing precision
If traditional nanoparticle production methods are used, then particle size reduction is achieved, but stability and prevention of aggregation require extensive use of surfactants
Solution Approach 1:
The patent extracts or eliminates surfactants from the formulation by using pure polymeric excipients that provide stabilization through steric hindrance and polymer-drug interactions rather than surfactant-based mechanisms
Solution Approach 2:
The invention uses composite formulations combining polymeric excipients (such as HPMC, PVP, or PEG) with the drug substance to create stable nanosuspensions that rely on polymer physics rather than surfactant chemistry for stabilization
4Ease of operation
If micronized drug particles are used, then handling and dosage form formulation are easier, but dissolution rate and bioavailability are insufficient
Solution Approach 1:
The patent segments the drug substance into nanometer-scale particles through the microfluidization process, dramatically increasing surface area and dissolution rate while maintaining the practical handling advantages of a particulate formulation
Solution Approach 2:
The invention changes the critical parameter of particle size from micrometer scale (micronized) to nanometer scale through microfluidization, fundamentally improving dissolution and bioavailability while preserving formulation convenience
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method produces stable nanosuspensions with improved bioavailability, suitable for long-term storage and administration, leading to increased solubility and efficacy, as demonstrated by enhanced plasma concentration-time profiles and dissolution rates.
Implementation Method 1
Turbulent flow and high shear forces cause particles collision, leading to particle diminution to the nanometer range
Implementation Method 2
Turbulent flow and high shear forces cause particles collision
Implementation Method 3
The high pressure applied and the high streaming velocity of the lipid can also lead to cavitation, additionally contributing to size diminution
Implementation Method 4
The surface modifiers prevent aggregation and/or Ostwald ripening of the nanoparticles during and after processing
Implementation Method 5
providing steric and/or ionic stabilization to the resulting nanometer-size drug particles
Implementation Method 6
providing steric and/or ionic stabilization to the resulting nanometer-size drug particles
Implementation Method 7
Surface modifiers are chosen from the list of pharmaceutically-acceptable substances and typically possess surface active properties capable of wetting the large drug crystals
Data Source
Figure 1A~1C
Figure 2A~2C
Figure 3
AI summary
Provided are compositions and methods for preparation and administration of an oral nanosuspension of a poorly soluble drug with improved bioavailability. The method is optimized through microfluidization process with water soluble polymeric excipients in the absence of surfactants.